Menu

Investors

2025 Full year and fourth quarter announcement

We announced our full year and fourth quarter 2025 results on Wednesday 4 February.

Q4 2025 resultsAnnual Report 2025
FY 2025 Luke Miels
Close video

We’re confident in our future

With our strong momentum and improving outlook for sustained growth through the decade, we're confident in our ability to deliver human health impact at scale, worldwide.

Why invest in GSK?

Speeches and presentations

Julie Brown

BNP Paribas Healthcare Conference

24 March 2026

Julie Brown, Chief Financial Officer, attended the BNP Paribas Healthcare Conference in London on Tuesday, 24 March 2026.

David Redfern

Barclays 28th Annual Global Healthcare Conference

11 March 2026

David Redfern, President Corporate Development, participated in a fireside chat at the Barclays 28th Annual Global Healthcare Conference in Miami, FL on Wednesday, 11 March 2026 at 11:30 am EST/4:30 pm GMT.

David Redfern

Leerink Partners Global Healthcare Conference

10 March 2026

David Redfern, President Corporate Development, attended the Leerink Partners Global Healthcare Conference in Miami, FL on Tuesday, 10 March 2026.

David Redfern

UBS European Healthcare Conference

04 March 2026

David Redfern, President Corporate Development, attended the UBS European Healthcare Conference in London on Wednesday, 4 March 2026.

GSK and 35 Pharma logo

GSK enters agreement to acquire 35Pharma Inc.

25 February 2026

Sell-side analysts calls with Nina Mojas, President, Global Product Strategy and Kaivan Khavandi, SVP, R&D Head, Respiratory, Immunology & Inflammation.

Shareholder information

Shareholder information

GSK dividend

GSK laboratory photo

Dividend calculators (GBp/USD)

Calculate an estimate of your dividend payment

GSK lab equipment photo

Dividend calendar

Details of our dividend timetable by quarter

GSK share price

Share price tool

Detailed information on GSK's share price, including an interactive chart

Go to share price tool

Behind the Science

Read our latest articles

Mapping disease at the cellular level: A single-cell revolution in drug discovery

Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus

'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk'

'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'

'Prevention is the best medicine to stop disease before it starts'

‘I was the sickest anyone could ever be’: Why young people are at risk of meningitis and what needs to change to reduce it

‘Digital biological twins and organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer’

‘I feel hopeless and frustrated’: Why patients living with incurable blood cancers need more treatment options

‘Finding the right treatment for my asthma and nasal polyps has transformed my life. I hope my experience can help others achieve the same’

‘How do we improve trust in prevention? The answer lies closer to home than you might think’

Behind the Science magazine
two scientists talking

Get in touch with our investor team

Investor contact details

You might also like

Pipeline

Our pipeline is focused on unlocking the science of the immune system and advanced technologies to develop innovative medicines and vaccines

Our leading scientists

Meet the world-leading scientists who are uniting science, technology and talent to get ahead of disease together.

Governance

At GSK we are committed to operating at the highest standards of corporate governance

Continue to Media